WuXi Biologics plans to sell its vaccine facility in Dundalk, Ireland to Merck & Co. for approximately $500 million. This comes as U.S. legislation aims to restrict WuXi Biologics business in the U.S. WuXi Biologics provided services for Merck at the site in Dundalk under a long-term contract to produce vaccines. The companies expect to complete the transaction in 1H25. The facility, which currently employs 200, will house an additional 150 workers by the end of this year, according...